Reuters logo
BRIEF-Myovant Sciences announces positive top-line results from Takeda's phase 3 study
October 3, 2017 / 2:43 AM / 2 months ago

BRIEF-Myovant Sciences announces positive top-line results from Takeda's phase 3 study

Oct 2 (Reuters) - Myovant Sciences Ltd

* Myovant sciences announces positive top-line results from Takeda’s phase 3 study evaluating efficacy and safety of Relugolix compared with Leuprorelin for treatment of uterine fibroids

* Says ‍Relugolix meets primary endpoint, achieving 82.2% response rate and demonstrating non-inferiority to Leuprorelin​

* Myovant Sciences Ltd says Takeda is conducting a second phase 3 trial

* Says ‍anticipates preliminary top-line data for second phase 3 trial in Q4 of 2017​

* Co currently conducting phase 3 clinical program consisting of 2 international, replicate pivotal clinical trials, initiated in Jan Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below